Core Insights - The article discusses the completion of over 100 million yuan financing by the ophthalmic medical device innovation company, Siairan Medical, led by Qianji Capital and Shunwei Capital, with continued support from existing shareholders [1] Company Overview - Siairan Medical was established in July 2022 and integrates research, production, and sales, focusing on providing precise and intelligent minimally invasive surgical solutions for ophthalmology [1] - The core team possesses extensive industry experience and has a complete capability in research, production, and commercialization [1] Product Development - The financing will primarily be used for the in-depth development of the company's first self-developed phacoemulsification and vitrectomy integrated machine product line [1] - The company aims to enrich its ophthalmic surgical equipment product matrix and accelerate the import substitution of high-end ophthalmic devices and the international expansion of its products [1] Market Position - Siairan Medical is dedicated to breaking the monopoly of foreign companies in the high-end ophthalmic surgical instrument sector and addressing critical instrument supply issues [1] - Current research and development products include the phacoemulsification and vitrectomy integrated machine and its supporting consumables, as well as digital surgical microscopes [1] Financing History - To date, the company has completed three rounds of financing, each exceeding 100 million yuan [1]